{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:06:54Z","timestamp":1792206414340,"version":"4.4.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy resulting either from congenital deficiency (cTTP) or acquired (immune) deficiency (iTTP) of A Disintegrin and Metalloprotease with ThromboSpondin-type 1 motif, member 13 (ADAMTS13). Deficiency of ADAMTS13 leads to disseminated platelet thrombosis and organ dysfunction. High mortality of cTTP is prevented by plasma infusion to replace the deficient protease, or more recently by infusion of recombinant ADAMTS13. Standard treatment of iTTP includes steroids, plasma exchange, and rituximab, with or without caplacizumab. Although standard treatment of iTTP improves mortality, refractory cases persist, indicating the need for additional treatment options. This review summarizes the status of novel treatment options for cTTP and iTTP, including additional recombinant ADAMTS13 products, ADAMTS13 gene therapies, plasma cell-directed therapies (bortezomib, daratumumab) as well as novel inhibitors of von Willebrand factor activity.<\/jats:p>","DOI":"10.3389\/fphar.2026.1841673","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:59:44Z","timestamp":1782136784000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Update in treatment options for congenital and immune thrombotic thrombocytopenic purpura"],"prefix":"10.3389","volume":"17","author":[{"given":"George M.","family":"Rodgers","sequence":"first","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah Health Sciences Center","place":["Salt Lake City, UT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura","volume":"133","author":"Alwan","year":"2019","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1056\/nejmoa2211113","article-title":"Recombinant ADAMTS13 for hereditary thrombotic thrombocytopenic purpura","volume":"387","author":"Asmis","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome-clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/nejmoa2402567","article-title":"Recombinant ADAMTS13 for immune thrombotic thrombocytopenic purpura","volume":"390","author":"Bendapudi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ajh.21881","article-title":"Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura","volume":"86","author":"Cataland","year":"2011","journal-title":"Am. J. Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ajh.23106","article-title":"Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura","volume":"87","author":"Cataland","year":"2012","journal-title":"Am. J. Hematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jtha.2025.10.012","article-title":"Successful use of recombinant ADAMTS13 in a pregnant patient with immune-mediated thrombotic thrombocytopenic purpura","volume":"24","author":"Cauchois","year":"2026","journal-title":"J. Thromb. Haemost."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1182\/blood.2022016640","article-title":"Race, rituximab, and relapse in TTP","volume":"140","author":"Chaturvedi","year":"2022","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.tmrv.2022.09.001","article-title":"Plasma cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP)","volume":"36","author":"Chen","year":"2022","journal-title":"Transfus. Med. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood.2020008021","article-title":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","volume":"137","author":"Coppo","year":"2021","journal-title":"Blood"},{"key":"B11","first-page":"1","article-title":"Caplacizumab and immunosuppression without plasma exchange in thrombotic thrombocytopenic purpura","volume":"9","author":"Coppo","year":"","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.eclinm.2025.103168","article-title":"Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura in an international multicenter retrospective cohort study (the capla 1000+ project)","volume":"30","author":"Coppo","year":"","journal-title":"E Clin. Med. Mar."},{"key":"B13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/MPH.0000000000002963","article-title":"Plasma exchange and N-acetylcysteine therapy in a case of congenital thrombotic thrombocytopenic purpura presenting with acute renal failure","volume":"47","author":"Coskun","year":"2025","journal-title":"J. Pediatr. Hematology\/Oncology"},{"key":"B14","article-title":"Efficacy and safety of caplacizumab in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume-title":"Thrombosis and Hemostasis Summit of North America","author":"De Matos","year":"2026"},{"key":"B15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/bjh.18192","article-title":"The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura","volume":"198","author":"Doyle","year":"2022","journal-title":"Brit J. Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40265-018-0989-0","article-title":"Caplacizumab: first global approval","volume":"78","author":"Duggan","year":"2018","journal-title":"Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s00277-023-05248-9","article-title":"N-acetylcysteine for thrombotic thrombocytopenic purpura: an observational case series study","volume":"102","author":"Espanol","year":"2023","journal-title":"Ann. Hematol."},{"key":"B18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-3-319-08717-7_5","article-title":"Hereditary deficiency of ADAMTS13 activity: upshaw-schulman syndrome","volume-title":"ADAMTS13: Biology and Disease","author":"Fujimura","year":"2015"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"Von Willebrand Factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1182\/asheducation-2018.1.548","article-title":"TTP: long -term outcomes following recovery","volume":"30","author":"George","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B21","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jtha.2024.10.034","article-title":"Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplcizumab era: italian multicenter study","volume":"23","author":"Giannotta","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.jtha.2025.12.021","article-title":"Endothelial injury to cognitive decline: a 12-month follow-up using CT-perfusion and diffusion MRI in immune thrombotic thrombocytopenic purpura","author":"Hannan","year":"2026","journal-title":"J. Thromb. Haemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","article-title":"Gain-of- function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"119","author":"Jian","year":"2012","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/j.1537-2995.2009.02232.x","article-title":"Anti-von willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura","volume":"49","author":"Knobl","year":"2009","journal-title":"Transfusion"},{"key":"B25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/jth.15637","article-title":"Alternate \u2013 day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura","volume":"20","author":"Kuhne","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1182\/blood.2023023780","article-title":"Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange","volume":"144","author":"Kuhne","year":"2024","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1038\/s41598-021-91165-8","article-title":"In vitro assessment and phase 1 randomized clinical trial of anfibatide, a snake venom derived antithrombotic agent targeting human platelet GP1b alpha","volume":"11","author":"Li","year":"2021","journal-title":"Sci. Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2138306","DOI":"10.1080\/09537104.2022.2138306","article-title":"Inherited ADAMTS13 mutations associated with thrombotic thrombocytopenic purpura: a short review and update","volume":"34","author":"Markham-Lee","year":"2023","journal-title":"Platelets"},{"key":"B30","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jtha.2023.11.030","article-title":"Targeted ADAMTS13 replacement therapy for thrombotic thrombocytopenia purpura","volume":"22","author":"Moroniti","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"B31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/archinte.1925.00120130092009","article-title":"An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. An undescribed disease","volume":"36","author":"Moschcowitz","year":"1925","journal-title":"Arch. Intern Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1076029618825309","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"B33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/nejmoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/jama.2025.3807","article-title":"Immune thrombotic thrombocytopenic purpura: a review","volume":"134","author":"Pishko","year":"2025","journal-title":"JAMA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group","volume":"325","author":"Rock","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/JBM.S395248","article-title":"Prolonged exposure to caplacizumab as rescue therapy in refractory immune thrombotic thrombocytopenic purpura","volume":"14","author":"Rodgers","year":"2023","journal-title":"J. Blood Med."},{"key":"B37","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood.V16.1.943.943","article-title":"Studies on thrombopoiesis. 1. A factor in normal human plasma required for platelet production: chronic thrombocytopenia due to its deficiency","volume":"16","author":"Schulman","year":"1960","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/nejmoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/nejmoa2314793","article-title":"Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura","volume":"390","author":"Scully","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1137019","DOI":"10.3389\/fmed.2023.1137019","article-title":"Immune thrombotic thrombocytopenic purpura: spotlight on long-term outcomes and survivorship","volume":"10","author":"Selvakumar","year":"2023","journal-title":"Front. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2024.285391","article-title":"Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism","volume":"110","author":"Simon","year":"2025","journal-title":"Haematologica"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.3389\/fimmu.2018.01646","article-title":"Concentration and subclass distribution of anti-ADAMTS13 IgG autoantibodies in different stages of acquired idiopathic thrombotic thrombocytopenic purpura","volume":"9","author":"Sinkovits","year":"2018","journal-title":"Front. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1182\/blood.2025029789","article-title":"Long-term follow-up outcomes in congenital thrombotic thrombocytopenic purpura","volume":"146","author":"Stubbs","year":"2025","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/jcm10030536","article-title":"Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management","volume":"10","author":"Sukumar","year":"2021","journal-title":"J. Clin. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM197806152982407","article-title":"Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia","volume":"298","author":"Upshaw","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0256024","DOI":"10.1371\/journal.pone.0256024","article-title":"Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the caplacizumab era","volume":"16","author":"van de Louw","year":"2021","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1182\/bloodadvances.2021005124","article-title":"Daratumumab for immune thrombotic thrombocytopenic purpura","volume":"6","author":"van den Berg","year":"2022","journal-title":"Blood Adv."},{"key":"B50","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ajh.27550","article-title":"Efficacy and safety of obinutuzumab in the treatment of immune -mediated thrombotic thrombocytopenic purpura","volume":"100","author":"Weisinger","year":"2025","journal-title":"Am. J. Hematol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/bjh.20101","article-title":"How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance","volume":"206","author":"Weisinger","year":"2025","journal-title":"Brit J. Haematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1182\/blood-2022-167054","article-title":"Silent cerebral infarction during immune TTP remission-prevalence, predictors and impact on cognition","volume":"140","author":"Yu","year":"2022","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7326\/0003-4819-138-2-200301210-00011","article-title":"Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab","volume":"138","author":"Zheng","year":"2003","journal-title":"Ann. Intern Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1182\/bloodadvances.2016000711","article-title":"Therapeutic efficacy of the platelet glycoprotein 1b antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura","volume":"1","author":"Zheng","year":"2016","journal-title":"Blood Adv."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1016\/j.jtha.2025.06.002","article-title":"2025 focused update of the 2020 guidelines for management of thrombotic thrombocytopenic purpura","volume":"23","author":"Zheng","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1016\/j.jtha.2025.06.014","article-title":"Molecular basis of thrombotic microangiopathy","volume":"23","author":"Zhou","year":"2025","journal-title":"J. Thromb. Haemost."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1841673\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:21:22Z","timestamp":1782285682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1841673\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":57,"alternative-id":["10.3389\/fphar.2026.1841673"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1841673","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1841673"}}